Phone No. : 2783400, 2783401 2783392
Fax No. : 2783311
E-Mail : ipclab@vsnl.net
Website : www.ipc.gov.in

INDIAN PHARMACOPOEIA COMMISSION
MIN. OF HEALTH & FAMILY WELFARE
GOVERNMENT OF INDIA
SECTOR -23, RAJ NAGAR, GHAZIABAD - 201002

No. IPC/7035/IP-2014/ER-007 **Dated**: 28-09-2015

To,

1. **DCG (I)/ CDSCO, Zonal Offices**
2. **All State Drug Controllers**
3. **Members of Scientific Body of the IPC**
4. **Members of Sub-committee of Scientific Body of the IPC**
5. **Government Analysts**
6. **Director of Drug Laboratories**
7. **IDMA/OPPI/BDMA/FSSAI/Small Scale Industry Associations**

ERRATA – 007 for IP 2014

As you are aware that the 7th edition of Indian Pharmacopoeia has become official from 1st April, 2014. Based on scientific inputs, some monographs, appendices needed corrections, accordingly an Errata – 007 is issued containing minor corrections. This is for notice and immediate compliance.

Yours faithfully,

(Dr. G. N. Singh)
Secretary-cum-Scientific Director

Encl:
ERRATA – 007 for IP 2014

Errata 007 to IP-2014

Allopurinol Tablets. Page 1013

Related substances. Under chromatographic System

Change **from:**

Time (in min)	Mobile phase A (per cent v/v)	Mobile phase B (per cent v/v)
0	100	100
30	0	100
40	0	100
42	100	0

to:

Time (in min)	Mobile phase A (per cent v/v)	Mobile phase B (per cent v/v)
0	100	0
30	0	100
40	0	100
42	100	0

Benzyl Alcohol. Page 1159.

Description.

Change **from:** A colourless liquid; almost odourless; taste, sharp and burning.

to: Clear, colourless, oily liquid.

Brimonidine Tartrate Eye Drops. Page 3813

pH.

Change **from:** 5.7 to 6.7

to: 5.7 to 8.0

Dexamethasone Tablets. Page 1523

Identification B.

Change **to:** In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Uniformity of Content. *Test solution.*

Change **from:** Finely crush one tablet, add sufficient quantity of a 0.002 per cent w/v solution of *hydrocortisone* in *methanol (50 per cent)* to produce a solution containing 0.0025 per cent w/v solution of Dexamethasone, shake for 10 minutes and filter through a glass-fiber filter paper (such as Whatman GF/C).

to: To one tablet, add sufficient *methanol (50 per cent)* to produce a solution containing 0.0025 per cent w/v of Dexamethasone, shake for 10 minutes and filter through glass-fibre filter.

Reference Solution.

Change **from:** A solution containing 0.0025 per cent w/v of *dexamethasone RS* and 0.002 per cent w/v of *hydrocortisone* (internal standard) in *methanol (50 per cent)*.

to: A solution containing 0.0025 per cent w/v of *dexamethasone RS* in *methanol (50 per cent)*.

Assay.

Delete test solution (b)

Change **from:** Test solution(a)

to: Test solution.

Reference Solution.

Change **to:** A solution containing 0.0125 per cent w/v of *dexamethasone RS* in *methanol (50 per cent)*.

After chromatographic system.

Change **from:** Calculate the content of $C_{22}H_{29}FO_5$ in the tablets.

to: Inject the reference solution and the test solution.

Calculate the content of $C_{22}H_{29}FO_5$ in the tablets.

Diloxanide Furoate. Page 1580

Loss on drying.

Change **from**: (2.3.19)

to: (2.4.19)

Doxofylline. Page 1625

Assay. After chromatographic system**.** line 1.

Change **from**: Inject reference solution (b).

to: Inject reference solution.

Para 2, line 1.

Change **from**: Inject reference solution (b).

to: Inject reference solution.

Ethacrynic Acid. Page 1693

Loss on drying.

Change **from**: (2.3.19)

to: (2.4.19)

Fosinopril Sodium. Page 1826

Water.

Change **from**: (2.4.19)

to: (2.3.43)

Frusemide Tablets . Page 1835

Identification B.

Change **from:** *4-dimethylaminobenzaldehyde solution.*

to: *4-dimethylaminobenzaldehyde Regent.*

Gemcitabine Hydrochloride. Page 1849

Related Substances. *Test solution (b).*
Change **to**: Dilute 1.0 ml of test solution (a) to 20.0 ml with water.

Hyoscine Butylbromide. Page 1926

Apo-compounds. Delete the test.

Hyoscine Hydrobromide. Page 1929

Apohyoscine. Delete the test.

Levodropropizine. Page 2084

Impurity C. Last Paragraph Line 3.
Delete. 0.5 times.

Mebendazole. Page 2154

Identification B. Delete the test
C. Change **to**: B

Mebendazole Tablets. Page 2154

Identification B. Delete the test
Delete the word **A**.

Mesalazine Prolonged-release Tablets. Page 2183

Related substances. Last paragraph, line 10.
Delete: "0.5 times"

Metformin Tablets. Page 2187

Identification. B. Line 5.
Change **from**: *dilute sodium hypochlorite solution*
to: *sodium hypochlorite solution (3 per cent Cl)*

Metolazone Tablets. Page 3900

Uniformity of content. *Test solution.*
Change **from:** Disperse 1 tablets in 3 ml of *water* and 100 ml of *methanol* with the aid of ultrasound for 30 minutes. If disintegration is not complete, sonicate for an additional 30 minutes. Shake by mechanical means for 30 minutes and dilute to 200.0 ml with *methanol*. Dilute a volume of this solution to obtain a solution containing 0.0005 per cent w/v of metolazone in *methanol.*

to: Disperse 1 tablets in 0.5 ml of *water* and 10.0 ml of *methanol* with the aid of ultrasound for 30 minutes. If disintegration is not complete, sonicate for an additional 30 minutes. Shake by mechanical means for 30 minutes and dilute to 20.0 ml with *methanol*. Dilute a volume of this solution to obtain a solution containing 0.0005 per cent w/v of metolazone in the mobile phase.

Reference solution

Change **from:** A 0.0005 per cent w/v solution of *metolazone RS* in *methanol.*

to: A 0.025 per cent w/v solution of *metolazone RS* in *methanol.* Dilute a volume of this solution to obtain a solution containing 0.0005 per cent w/v solution of *metolazone RS* in mobile phase.

Assay. *Test solution.* Lines 4,5 and 6.
Change **from**: Dilute a volume of this solution to obtain a solution containing 0.0005 per cent w/v of metolazone in *methanol.*

to: Dilute a volume of this solution to obtain a solution containing 0.0005 per cent w/v of metolazone in mobile phase.

Reference solution.
Change **to**: A 0.025 per cent w/v solution of *metolazone RS* in *methanol.* Dilute a volume of this solution to obtain a solution containing 0.0005 per cent w/v solution of *metolazone RS* in mobile phase.

Myristic Acid. Page 2270

Lead. Last line
Change **from:** Calculate the content of lead, in the substance under examination.

to: Calculate the content of lead, in the substance under examination. (2 ppm)

Assay. Last line
Change **from:** Calculate the content $C_{14}H_{28}O_2$.

to: Calculate the content $C_{14}H_{28}O_2$ by area normalization method.

Orphenadrine Citrate. Page 2387

Loss on drying.
Change **from**: (2.3.19)
to: (2.4.19)

Orphenadrine Hydrochloride. Page 2388

Loss on drying.
Change **from**: (2.3.19)
to: (2.4.19)

Piperazine Citrate. Page 2504

Water.
Change **from**: (2.4.19)
to: (2.3.43)

Teicoplanin. Page 2828

Heavy metals. Line 1.
Change **from:** 0.5 g
to: 1.0 g

Theophylline Injection Page 2852

Assay. Line 3

Change **from**: 0.008 percent
to : 0.0008 percent

Triethyl Citrate. Page 2915

Water.

Change **from**: (2.4.19)

to: (2.3.43)

VETERINARY MONOGRAPHS

Spectinomycin Hydrochloride. Page 3566

Assay. After chromatographic system. Para 1, line 4.

Change **from**: test solution (a).

to: test solution (b).

Spectinomycin Injection. Page 3568

Assay. After chromatographic system. Para 1, line 4.

Change **from**: test solution (a).

to: test solution (b).

Last line**.**

Change **from:** $C_{14}H_{24}N_2O_7,2HCl$

to: $C_{14}H_{24}N_2O_7$.